Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The company said the virtual event on Oct. 23 will discuss fetal growth restriction, the rationale for DM199 and preliminary first-cohort findings from its Phase 2 early-onset FGR trial. Enrollment in the first cohort of six participants is complete and dosing has begun in the second cohort.
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it will host a virtual key opinion leader (KOL) event on October 23, 2026 at 8:00am…